PATENT CLAIM ANALYSIS

Application Number: 16050516
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "254060"]

Abstract:
Methods of treating neuroblastoma associated with a deregulated protein kinase activity are disclosed. The treatment may include administration of substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts therefor, as degined in the specification.

Claim (Index 11):
The method of  claim 9 , wherein the compound is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.20513
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14623904', '14953969', '16039196', '12520387', '12096979']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8418804584321036
- 35 USC 102 Novelty (BERT): 0.6185825512488101
- Combined Prediction Score: 0.8195506677137742
- Mean Citation Score: 535.479192
- Max Citation Score: 664.5318
- Similarity Product: 466.7760674617052

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test